© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
August 17, 2020
Satralizumab represents only the second targeted treatment for NMOSD and the first cleared for at-home administration.
August 12, 2020
The approval is based on findings from a phase 2 clinical trial.
August 07, 2020
Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.